Application of animal-free recombinant bioactive proteins to improve the growth performance of cell lines for viral vaccines

摘要

The use of mammalian cell culture for the production of both pharmaceutical proteins and viral vaccines has grown dramatically over recent decades. The increased demand for cell-derived products has been accompanied by rapid developments in process technology and radical changes in the design of culture media. The progressive availability of relevant bioactive proteins using recombinant DNA technology has allowed the replacement of animal-derived components in the production process; this has assisted the efforts of regulatory bodies to minimise the potential risk to product users. The use of bioactive proteins has also contributed to greater consistency in process performance and provided the scope to elevate process yields. Examples of typically used bioactive proteins are listed in Table 1. Although individual proteins may have a significant effect on cell growth and productivity, the effect on performance can be enhanced further when particular proteins are used in combination. The industrial application of these proteins has largely focused on recombinant Chinese Hamster Ovary (CHO) cell lines producing pharmaceutical proteins. This poster presents the results of a preliminary study where the growth responses to a selection of bioactive proteins (Insulin-like growth factor, Epidermal growth factor, Transferrin and Albumin) were tested in three cell lines that are important in the production of viral vaccines.